Combining Immunotherapy and Chemotherapy in NSCLC

Content Outline

Chemotherapy Promotes Immunogenic Responses Through Multiple Mechanisms

Chemotherapy Promotes Immunogenic Responses Through Multiple Mechanisms

Combinations in NSCLC Updated Approvals in 2019

Anti-PD-1 Monotherapy Long-Term Follow-Up Continues to Impress

Pooled Long-Term Analysis of CheckMate-017/-057*

Recent Updates to KEYNOTE-189

KEYNOTE-021 Cohort G Longer-Term Follow-Up Continues to Favor Pembrolizumab

IMpower150 Identifies Key Subgroups That May Benefit From Quadruplet Therapy

Is Liver Metastasis a Biomarker for Selection of Combination Regimens?

Optimizing Treatment Selection for PD-L1-High NSCLC Single Agent or Combo?

IMpower132 Confirming Chemo-Immunotherapy Combo Efficacy

Immune Checkpoint Combination for Squamous-Cell Disease IMpower131

CheckMate-227 Focusing on Chemo-Immunotherapy in PD-L1-Negative NSCLC

Tumor Mutational Burden as a Biomarker of Immunotherapy

Exploratory MYSTIC Findings Demonstrating an Effect of High TMB on Immune Priming

Patient Case

Considerations for Optimal First-Line Treatment Selection, High PD-L1 and TMB

Optimal Treatment Selection for PD-L1-Low (20%) or Negative (<1%) NSCLC New Considerations

Following ESMO Guidelines for Non Squamous NSCLC First-Line Treatment

Important Ongoing Studies in Lung Cancer

The INSIGNA Trial Defining an Optimal Sequence for Advanced NSCLC

Keys to Managing Immunologic Adverse Events

Is Re-Challenge With Immunotherapy Feasible After a Serious Adverse Event?

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)